Coordinating Center for the Drug Induced Liver Injury Network (DILIN)

$981,711U01FY2016DKNIH

Duke University, Durham NC

Investigators

Linked publications & trials

Paper 38988034 Paper 38874448 Paper 37552102 Paper 36848311 Paper 36496055 Paper 36252717 Paper 36152763 Paper 35973149 Paper 34953957 Paper 34400337 Paper 33899326 Paper 33257199 Paper 33007507 Paper 32270503 Paper 32251016 Paper 32205565 Paper 31991029 Paper 31302142 Paper 31169665 Paper 30934130 Paper 30927209 Paper 30865042 Paper 30766772 Paper 30664875 Paper 30359443 Paper 30138689 Paper 30013178 Paper 29966706 Paper 29357190 Paper 29306044 Paper 29119413 Paper 28762375 Paper 28555362 Paper 28543844 Paper 28323125 Paper 28161910 Paper 28121193 Paper 28043905 Paper 27981596 Paper 27860186 Paper 27677775 Paper 27648552 Paper 27311619 Paper 27189593 Paper 27142670 Paper 27003146 Paper 26679098 Paper 26601797 Paper 26346867 Paper 26286715 Paper 25754159 Paper 25724701 Paper 25579757 Paper 25528012 Paper 25446466 Paper 25418487 Paper 25111234 Paper 25043597 Paper 24879983 Paper 24700436 Paper 24681128 Paper 24661785 Paper 24386086 Paper 24362054 Paper 24037963 Paper 23650938 Paper 23625293 Paper 23388845 Paper 23377559 Paper 23333219 Paper 23212393 Paper 22968431 Paper 22711078 Paper 22594502 Paper 22510500 Paper 22403816 Paper 21855518 Paper 21788760 Paper 21570397 Paper 21356330 Paper 21038416 Paper 20815829 Paper 20564754 Paper 20512999 Paper 20170750 Paper 20104221 Paper 19132805 Paper 18955056 Paper 18798340

Abstract

DESCRIPTION (provided by applicant): The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have proposed the continuation of the Drug-Induced Liver Injury Network (DILIN). As described in the RFA, DILIN will be a network composed of up to 5 Clinical Centers (CCs) with expertise in diagnosis and management of DILI and a Data Coordinating Center (DCC) with expertise in the management of multicenter studies and clinical and translational datasets. The purpose of this research program is to enhance the enrollment of cases and controls (when justified) from a diverse demographic and wide geographic distribution. The major aim of the network study is to pursue pharmacogenetic analyses to find predictive biomarkers as well as genetic fingerprints useful for elucidating the pathogenesis of Drug-Induced Liver Injury (DILI) and ultimately for developing specific means of prevention and or treatment. The Duke Clinical Research Institute (DCRI) proposes to continue as the DCC for DILIN. In this role, we will apply our extensive experience and research infrastructure to coordinate, support and facilitate the activities of the DILIN network. In particular, we will atted to the following specific aims: (1) Explore and Determine the use of LiverTox case report for enrollment from a wide demographic and geographic distribution throughout US; (2) Support protocol development of pharmacogenetic and biomarker studies and studies with intervention strategies to prevent and treat DILI; (3) Support development of a validated, computer-based instrument and diagnosis of DILI which is accurate, simple and practical for clinicians; (4) Support manuscript preparation; (5) Provide overall network Coordination and Logistics; (6) Ensure quality assurance and continue data management activities; (7) Contribute to maintain LiverTox; (8) Provide statistical leadership in design and analysis Issues; (9) Support ancillary studies.

View original record on NIH RePORTER →